Vildagliptin, with or without metformin, for fatty liver and diabetes
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This trial studies how vildagliptin compares to vildagliptin plus metformin in people who have fatty liver disease along with type 2 diabetes. It may help find the safest and most effective way to improve liver health and diabetes control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have fatty liver disease (NAFLD) and type 2 diabetes
- You do not have viral hepatitis (for example, hepatitis B or C)
- Your Child-Pugh score is 6 or less (a measure of liver function severity)
- You do not have kidney problems (renal impairment)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two medicines, vildagliptin and metformin, to see which works better for women with Polycystic Ovary Syndrome (PCOS). The goal is to find a safe and effective treatment that may help manage PCOS symptoms.
This study tests a combination of two diabetes medicines to see how well they improve blood sugar control, fat metabolism, and the health of your pancreas in people who have both type 2 diabetes and fatty liver disease. The goal is to find treatments that help both conditions at the same time.
This study tests whether a medicine called henagliflozin can help reduce fat in the liver for people with type 2 diabetes and non-alcoholic fatty liver disease. It may help improve liver health and blood sugar control at the same time.
This study tests whether adding dapagliflozin (a diabetes drug) to metformin can lower a growth factor (IGF-1) that may affect fatty liver disease in men. It aims to see if this combined treatment improves liver health and diabetes control.
This trial is testing if adding a combination of SGLT-2 inhibitor and GLP-1 receptor agonist to metformin can improve blood sugar control in people with type 2 diabetes who are not meeting their goals on metformin alone or with one other pill.
This trial tests whether vildagliptin, a diabetes drug, can slow the progression of early Parkinson's disease. It is for people who have been diagnosed within the past three years and are already taking stable Parkinson's medications.
Hear when a new DM trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.